Skip to main content

Tyme Technologies, Inc. (TYME)

NASDAQ: TYME · IEX Real-Time Price · USD
0.720
-0.070 (-8.86%)
At close: Dec 3, 2021 4:00 PM
0.730
0.010 (1.389%)
After-hours:Dec 3, 2021 7:46 PM EST
Market Cap136.04M
Revenue (ttm)n/a
Net Income (ttm)-24.80M
Shares Out188.95M
EPS (ttm)-0.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,231,085
Open0.790
Previous Close0.790
Day's Range0.700 - 0.800
52-Week Range0.660 - 4.990
Beta0.87
AnalystsBuy
Price Target9.50 (+1,219.4%)
Earnings DateNov 8, 2021

About TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for t...

IndustryBiotechnology
Founded2011
Employees17
Stock ExchangeNASDAQ
Ticker SymbolTYME
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for TYME stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 1,219.44% from the latest price.

Price Target
$9.50
(1,219.44% upside)
Analyst Consensus: Buy

News

TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Res...

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financ...

3 weeks ago - Business Wire

TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced ...

1 month ago - Business Wire

TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

1 month ago - Business Wire

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patien...

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (“TYME” or the “Company”) (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

2 months ago - Business Wire

TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

3 months ago - Business Wire

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced fi...

3 months ago - Business Wire

TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

4 months ago - Business Wire

Tyme Technologies Stock Rallies: A Technical Analysis

Shares of Tyme Technologies, Inc. (NASDAQ: TYME) may have just crashed into a wall of sellers. This means the rally may be over.

4 months ago - Benzinga

TYME Stock: The Cancer Treatment News That's Boosting Tyme Today

TYME stock is making big moves today after it received patent approval for its cancer treatment. Now, it will move into deeper development.

4 months ago - InvestorPlace

Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notific...

4 months ago - Business Wire

Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday

Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?

Other symbols:AXLAIBIO
5 months ago - PennyStocks

Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings

Tyme Technologies Inc (NASDAQ: TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021.

5 months ago - Benzinga

Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Repo...

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (Nasdaq:TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reporte...

5 months ago - Business Wire

3 Biotech Penny Stocks That Are Popular on Reddit Right Now

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other symbols:CRBPEYES
6 months ago - PennyStocks

Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and In...

Other symbols:ADXSSESNTTOO
6 months ago - PennyStocks

Best Penny Stocks in 2021 So Far? Here's 4 You Should Check Out

These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?

Other symbols:ABEOLOTZOCG
6 months ago - PennyStocks

TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today annou...

6 months ago - Business Wire

3 Penny Stocks To Watch Under $2 Making Big Moves Today

Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Pic...

Other symbols:ADXSNGD
6 months ago - PennyStocks

2 Meme Stocks Test Resistance For A Larger Move

Express Inc (NYSE:EXPR) and Tyme Technologies Inc (NASDAQ:TYME) skyrocketed in January and February after gaining the attention of the WallStreetBets community. Now known as meme stocks, along with Game...

Other symbols:EXPR
6 months ago - Benzinga

TYME Appoints Frank L. Porfido as Chief Financial Officer

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

6 months ago - Business Wire

TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

6 months ago - Business Wire

TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan...

8 months ago - Business Wire

Why Tyme Technologies Stock Is Taking Off Today

The company closed a $100 million public stock offering.

9 months ago - The Motley Fool

TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it clos...

9 months ago - Business Wire

Why Tyme Stock Got Demolished Today

The clinical-stage biotech provides investors with a quarterly update.

9 months ago - The Motley Fool